Details of the Drug Combinations

General Information of This Drug (ID: DMFRM1I)

• Drug Name: Canagliflozin (DMFRM1I)
• Synonyms: 842133-18-0; Invokana; Canagliflozin anhydrous; canagliflozin hemihydrate; UNII-6S49DGR869; JNJ-28431754; JNJ 24831754ZAE; Canagliflozin hydrate; TA-7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; 928672-86-0

Indication

Non-insulin dependent diabetes; ICD 11: 5A11; Status: Approved [1]; Type-2 diabetes; ICD 11: 5A11; Status: Approved [2]; Diabetic nephropathy; ICD 11: GB61.Z; Status: Phase 3 [3]; Type-1 diabetes; ICD 11: 5A10; Status: Phase 2 [4]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Canagliflozin + Sitagliptin	DC96HDS	Sitagliptin	Type2 Diabetes Mellitus	[5]
Canagliflozin + Probenecid	DCK7KCA	Probenecid	Type 2 Diabetes Mellitus	[6]
Canagliflozin + Digoxin	DCY6THR	Digoxin	Type2 Diabetes Mellitus	[7]
Dapagliflozin + Canagliflozin	DCGKLRH	Dapagliflozin	Diabetes Mellitus, Type 2	[8]
Glimepiride + Canagliflozin	DCZUJIB	Glimepiride	Type2 Diabetes Mellitus	[5]
Liraglutide + Canagliflozin	DCIVP8Z	Liraglutide	Type 2 Diabetes Mellitus	[9]
Metformin + Canagliflozin	DCDZWCY	Metformin	Type-2 diabetes	[10]
MLN1117 + Canagliflozin	DCNNTP4	MLN1117	Breast Cancer	[11]
Verapamil + Canagliflozin	DCTQSQP	Verapamil	Type 2 Diabetes Mellitus	[6]
Canagliflozin + Phentermine	DCOHJTR	Phentermine	Obesity	[12]
Canagliflozin + Aminohippuric acid	DCZV9V9	Aminohippuric acid	Type 2 Diabetes	[13]
Metformin + Canagliflozin	DCRY3FB	Metformin	Polycystic Ovary Syndrome	[14]

References

• [1] Canagliflozin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4582).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT02956044) Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
• [6] ClinicalTrials.gov (NCT03296800) Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
• [7] ClinicalTrials.gov (NCT03197324) Bexagliflozin Drug/Drug Interaction Study With Digoxin
• [8] ClinicalTrials.gov (NCT03249506) Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
• [9] ClinicalTrials.gov (NCT02324842) Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
• [10] ClinicalTrials.gov (NCT01508182) A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT04073680) A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
• [12] ClinicalTrials.gov (NCT02243202) Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
• [13] ClinicalTrials.gov (NCT05507892) Renal Mechanism of SGLT2 Inhibition
• [14] ClinicalTrials.gov (NCT06256289) Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome